Elizabeth R. Plimack, MD, on RCC: Outcomes With Pembrolizumab Plus Axitinib

February 23, 2021 By The ASCO Post Staff

Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses phase III results from the KEYNOTE-426 study—specifically, an exploratory subgroup analysis of patients with advanced renal cell carcinoma who were randomly assigned to receive pembrolizumab plus axitinib and completed 2 years of treatment (Abstract 327).

Related Content